603567.SHG Heilongjiang ZBD Pharmaceutical Co Ltd
- Market cap
- CNY 4.73B
- P/E
- -
- P/B
- 0.79x
- ROE
- -11.1%
- Dividend yield
- 5.85%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603567.SHG undervalued?
Graham numberThe Graham number of Heilongjiang ZBD Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Heilongjiang ZBD Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Heilongjiang ZBD Pharmaceutical Co Ltd yet.
Heilongjiang ZBD Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the pharmaceuticals business in China. The company researches, develops, produces, and sale traditional Chinese medicine preparations, biological agents, and chemical agents, as well as involved in the pharmaceutical and Chinese medicinal materials trade; and leasing business. It also engages in pharmaceutical manufacturing; contract manufacturing of pharmaceuticals; pharmaceutical retail and wholesale; testing and inspect…
Full company profileHeilongjiang ZBD Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Heilongjiang ZBD Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.39B | 3.14B | 2.78B | 3.29B | 3.40B | 4.13B | 4.21B | 3.14B | 2.70B | 798M | 543M |
| Gross Profit | 1.50B | 1.75B | 1.91B | 1.91B | 1.89B | 1.30B | 675M | 1.29B | 1.37B | -22.1M | 19.8M |
| Operating Income | 491M | 648M | 574M | 547M | 511M | 456M | 298M | 473M | 523M | -418M | -298M |
| EBITDA | 610M | 737M | 749M | 705M | 741M | 406M | -59.8M | 364M | 757M | -1.31B | -659M |
| Net Income | 510M | 521M | 462M | 409M | 436M | 332M | 185M | 473M | 438M | -1.37B | -643M |
| EPS | 0.60 | 0.61 | 0.54 | 0.48 | 0.51 | 0.38 | 0.20 | 0.50 | 0.47 | -1.45 | -0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 6.42B | 6.89B | 8.18B | 9.02B | 10.2B | 11.5B | 11.7B | 12.5B | 12.7B | 10.6B | 10.00B |
| Total Liabilities | 2.11B | 2.21B | 3.20B | 3.77B | 4.73B | 4.45B | 4.57B | 4.43B | 4.42B | 4.36B | 4.16B |
| Shareholders' Equity | 4.30B | 4.67B | 4.97B | 5.24B | 5.49B | 7.04B | 7.10B | 7.55B | 7.80B | 6.28B | 5.80B |
| Cash & Short-term Investments | 1.18B | 1.80B | 2.25B | 2.55B | 1.54B | 1.55B | 1.00B | 1.47B | 1.05B | 78.9M | 60.0M |
| Total Debt | 1.43B | 1.40B | 2.15B | 2.69B | 3.21B | 2.94B | 2.93B | 3.15B | 2.85B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.8M | 853M | 367M | 221M | 155M | -434M | -327M | -458M | 164M | 322M | - |
| Capital Expenditure | 319M | 492M | 420M | 179M | 869M | 449M | 404M | 95.1M | 189M | 68.5M | 36.2M |
| Free Cash Flow | -303M | 361M | -52.2M | 42.1M | -713M | -883M | -731M | -573M | -24.8M | 254M | 136M |
| Ratios | |||||||||||
| ROE | 11.8% | 11.2% | 9.3% | 7.8% | 7.9% | 4.7% | 2.6% | 6.3% | 5.6% | -21.8% | -11.1% |
| ROA | 7.9% | 7.6% | 5.7% | 4.5% | 4.3% | 2.9% | 1.6% | 3.8% | 3.4% | -12.9% | -6.4% |
| Net Profit Margin | 21.3% | 16.6% | 16.6% | 12.4% | 12.8% | 8.0% | 4.4% | 15.1% | 16.2% | -171.2% | -118.5% |
| Debt to Equity | 0.33x | 0.30x | 0.43x | 0.51x | 0.58x | 0.42x | 0.41x | 0.42x | 0.37x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Heilongjiang ZBD Pharmaceutical Co Ltd dividends
- Dividend yield
- 5.85%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 20, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 277M | 0.29 | - |
| 2024 | CNY 324M | 0.34 | 74.0% |
| 2023 | CNY 158M | 0.17 | 33.5% |
| 2022 | CNY 99.8M | 0.11 | 53.8% |
| 2021 | CNY 144M | 0.17 | 43.3% |
| 2020 | CNY 184M | 0.22 | 42.2% |
| 2019 | CNY 139M | 0.16 | 34.1% |
| 2018 | CNY 233M | 0.27 | 50.3% |
| 2017 | CNY 202M | 0.24 | 38.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jun 13, 2016.
Who owns Heilongjiang ZBD Pharmaceutical Co Ltd
- Insiders 60.24%
- Institutions 2.60%
- Public & others 37.17%
- Shares outstanding 940M
- Free float 444M
Heilongjiang ZBD Pharmaceutical Co Ltd company profile
- Company name
- Heilongjiang ZBD Pharmaceutical Co Ltd
- Ticker
- 603567.SHG
- ISIN
- CNE100002219
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,961
- Fiscal year end
- December
- Address
- No. 8, Yantai Road, Harbin, China, 150060
- Phone
- 86 45 1868 11969
- Website
- zbdzy.com
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the pharmaceuticals business in China. The company researches, develops, produces, and sale traditional Chinese medicine preparations, biological agents, and chemical agents, as well as involved in the pharmaceutical and Chinese medicinal materials trade; and leasing business. It also engages in pharmaceutical manufacturing; contract manufacturing of pharmaceuticals; pharmaceutical retail and wholesale; testing and inspection services; pharmaceutical internet information services; laboratory animal production; and laboratory animal management. The company offers medicines in the field of cardiovascular and cerebrovascular, anti-infectives, respiratory system drugs, tumors, and antiviral drugs diseases. Heilongjiang ZBD Pharmaceutical Co., Ltd. was founded in 1996 and is based in Harbin, China.
Heilongjiang ZBD Pharmaceutical Co Ltd management
4- Mr. Jiujiang YanGM & Non-Independent Director · born 1978
- Ms. Tianzhu LiDeputy General Manager · born 1978
- Ji LangInvestor Relations Director
- Mr. Song ZhengNon-Independent Director & Board Secretary · born 1990